This Study Will Evaluate The Relationship Between Plasma Drug Levels And Receptor Binding In Brain Using PET (Positron Emission Tomography) In Healthy Volunteers

Phase 1 Completed 12 enrolled Pfizer Yale University · collab

Non-randomizedSingle-groupOpen-labelBasic science

Summary

The purpose of this study is to evaluate the relationship between plasma drug levels and receptor binding in brain using PET; and to evaluate safety and tolerability after a single administration of PF-05212377 in healthy volunteers

Timeline

Start: 2010-12
Primary completion: 2011-05
Completion: 2011-05

Publications

Sawant-Basak A, Chen L, Lockwood P, Boyden T, Doran AC, Mancuso J, Zasadny K, McCarthy T, Morris ED, Carson RE, Esterlis I, Huang Y, Nabulsi N, Planeta B, Fullerton T. Investigating CNS distribution of PF-05212377, a P-glycoprotein substrate, by translation of 5-HT6 receptor occupancy from non-human primates to humans. Biopharm Drug Dispos. 2023 Feb;44(1):48-59. doi: 10.1002/bdd.2351. Epub 2023 Mar 13.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	PF-05212377	Small molecule	0.25 mg	Oral
Subject	PF-05212377	Small molecule	5 mg	Oral
Subject	PF-05212377	Small molecule	15 mg	Oral

Indications

No indication recorded.